EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

All‐Oral Shorter Treatment Regimens for Multidrug‐ and Rifampicin‐Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao PDR

Vibol Iem, Sakhone Suthepmany, Vongkham Inthavong, Anousone Sisouvanh, Khamloun Choumlivong, Kyung Hyun Oh, Philipp du Cros, Fatimata Bintou Sall, Corinne S Merle, Jacques Sebert, Donekham Inthavong

Tropical Medicine & International Health · 2025

DOI: 10.1111/tmi.70041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tropical Medicine & International Health, 2025. Verfasst von Vibol Iem und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Tuberculosis Research, Liverpool School of Tropical Medicine, Liverpool, UK. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Quality of Life, Rifampin, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug‐resistant tuberculosis remains a major public health challenge in Lao PDR, with low second‐line treatment uptake and suboptimal outcomes. To improve effectiveness, safety, and tolerability, a shorter all‐oral regimen for multidrug‐ and rifampicin‐resistant tuberculosis (MDR/RR‐TB) was introduced under the TDR Short, all‐Oral Regimens for Rifampicin‐resistant Tuberculosis (ShORRT) initiative.

Methods

A retrospective and prospective comparative cohort study was conducted across five drug‐resistant tuberculosis treatment centres from January 2020 to December 2023. Two programmatic cohorts were analysed during partially overlapping calendar periods: a standard injectable‐containing regimen cohort and an all‐oral regimen cohort. Outcomes were assessed at the end of treatment and 12 months post‐treatment. Safety was evaluated through adverse events, including serious adverse events and adverse events of special interest. Health‐related quality of life was measured using EQ‐5D‐5L and EQ‐VAS tools.

Results

Among 126 participants, 65 received the all‐oral regimen and 61 the standard regimen. Treatment success was higher in the all‐oral group (90.8% vs. 80.3%), with lower mortality (7.5% vs. 16.4%) and fewer serious adverse events (12.3% vs. 19.7%). Anaemia was more common in the all‐oral group (46.2%), while hepatotoxicity and QTcF prolongation were more frequent in the standard group. Both groups showed improvements in health‐related quality of life, but greater recovery in mobility, daily activities, and anxiety reduction was observed in the all‐oral group. Between group differences did not reach statistical significance. No cases of tuberculosis recurrence were reported at 12‐month follow‐up in either group.

Conclusion

In this programmatic setting, the all‐oral, bedaquiline and linezolid‐based regimen demonstrated high effectiveness and acceptable safety. Non‐significant trends favoured the all‐oral regimen for treatment success, mortality, and quality of life, consistent with but not definitive for improved outcomes. These findings support the transition to all‐oral regimens as the preferred approach for drug‐resistant tuberculosis care, while acknowledging the observational design and limited power.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantQuality of LifeRifampinAntitubercular AgentsHumansMaleFemaleLaosAdultRetrospective StudiesMiddle AgedProspective StudiesAdministration, OralTreatment Outcome

Stichwörter der Autor:innen

all‐oral regimendrug‐resistant tuberculosishealth‐related quality of lifeprogrammatic implementationrifampicin‐resistant TBtreatment outcomes

Substanzen

RifampinAntitubercular Agents

Autor:innen und Institutionen

  • Centre for Tuberculosis Research, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Office of the WHO Representative in Lao PDR, Vientiane, Lao PDR.
  • National Tuberculosis Control Center, Vientiane, Lao PDR.
  • Sethathirath Hospital, Vientiane, Lao PDR.
  • World Health Organization, Regional Office for the Western Pacific, Manila, Philippines.
  • Burnet Institute, Melbourne, Australia.

Förderung

  • World Health Organization
  • Ministry of Health

Zitieren

APA

Iem, V., Suthepmany, S., Inthavong, V., Sisouvanh, A., Choumlivong, K., Oh, K. H., du Cros, P., Sall, F. B., Merle, C. S., Sebert, J., & Inthavong, D. (2025). All‐Oral Shorter Treatment Regimens for Multidrug‐ and Rifampicin‐Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao PDR. Tropical Medicine & International Health. https://doi.org/10.1111/tmi.70041

Vancouver

Iem V, Suthepmany S, Inthavong V, Sisouvanh A, Choumlivong K, Oh KH, et al. All‐Oral Shorter Treatment Regimens for Multidrug‐ and Rifampicin‐Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao PDR. Tropical Medicine & International Health. 2025. doi:10.1111/tmi.70041

BibTeX
@article{Iem2025,
  author = {Iem, Vibol and Suthepmany, Sakhone and Inthavong, Vongkham and Sisouvanh, Anousone and Choumlivong, Khamloun and Oh, Kyung Hyun and du Cros, Philipp and Sall, Fatimata Bintou and Merle, Corinne S and Sebert, Jacques and Inthavong, Donekham},
  title = {All‐Oral Shorter Treatment Regimens for Multidrug‐ and Rifampicin‐Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao PDR},
  journal = {Tropical Medicine & International Health},
  year = {2025},
  doi = {10.1111/tmi.70041}
}
Kostenlos starten →